Key Inclusion Criteria:  ECOG Performance Status <= 2 Histologically cytologically confirmed solid tumor Relapsed, is refractory to, or intolerant of standard of care therapy No available approved therapy that may provide clinical benefit per Investigator Measurable or evaluable disease by RECISTv1.14 Life expectancy of > 12 weeks per Investigator Willingness to comply with the study schedule and all study requirements  Key Exclusion Criteria:  Participating in any other interventional clinical study Previous exposure to an anti-CD47 or SIRPα antibody ≤ 28 days (or 5 half-lives if shorter) between of systemic anti-tumor treatment (e.g., chemotherapy, endocrine therapy, immunotherapy, cellular therapy) and C1D1 ≤ 28 days from prior irradiation (≤ 7 days from limited field irradiation for control of symptoms) and C1D1 Known central nervous system (CNS) involvement with tumor (e.g., metastases, meningeal carcinomatosis) Active second malignancy requiring ongoing systemic treatment History of primary immunodeficiency disorders History of active pulmonary tuberculosis